Lack of HER-2 gene amplification in non-Hodgkin lymphoma using chromogenic in situ hybridisation test

Leukemia and Lymphoma

Volumn 50, Issue 5, 2009, Pages 736-740

  Szvalb, Sergio ^a   Stein, Moshe ^b   Gershuny, Anthony ^c   Gez, Eli ^b   Hadary, Amram ^a   Zidan, Jamal ^a,d  

^a Rebecca Sieff Government Hospital   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

^c OLDCHURCH HOSPITAL   (United Kingdom)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

CISH test; HER 2; Non Hodgkin lymphoma; Prognostic factors

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PREDNISONE; RITUXIMAB; VINCRISTINE;

ACCURACY; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CHROMOGENIC IN SITU HYBRIDIZATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY ANALYSIS; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; ARABS; CHROMOGENIC COMPOUNDS; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; IN SITU HYBRIDIZATION; JEWS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 68449102961     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190902801820     Document Type: Article

References (28)

1. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244: 707-712.
2. Schneider PM, Hung MC, Chiocca SM, Manning J, Zhao XY, Fang K, et al. Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer. Cancer Res 1989;4:4968-4971.
3. Yoshida K, Tsuda T, Matsumura T, Tsujino T, Hattori T, Ito H, et al. Amplification of epidermal growth factor receptor (EGFR) gene and oncogenes in human gastric carcinomas. Virchows Arch B Cell Pathol Incl Mol Pathol 1989;57: 285-290.
4. Slichenmyer W, Fry D. Anticancer therapy targeting the Erb B family of receptor tyrosine kinases. Semin Oncol 2001;28: 67-79.
5. Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast. J Natl Cancer Inst 1998;90:1346-1360.
6. Hortobagyi G. Optimal duration therapy with trastuzumab. Semin Oncol 2001;28 (Suppl 18): 1-2.
7. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-1684.
8. Fisher SG, Fisher RI. The epidemiology of non-Hodgkin's lymphoma. Oncogene 2004;23:6524-6534.
9. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non- Hodgkin's lymphoma. N Engl J Med 1993;329:987-994.
10. Zidan J, Hussein O, Basher W, Zohar S. Serum CA125: A tumor marker for monitoring response to treatment and follow-up in patients with non-Hodgkin's lymphoma. Oncologist 2004;9:417-421.
11. Rastetter W, Molina A, White C. Rituximab: Expanding role in therapy for lymphomas and autoimmune diseases. Annual Rev Med 2004;55:477-503.
12. Bairey O, Pazgal I, Okon E, Shaklai M, Morgenshtern S. Lack of HER-2/neu expression in Hodgkin and non-Hodgkin lymphoma, an immunohistochemical study. Arch Pathol Lab Med 2002;126:574-576.
13. Luftner D, Genvresse I, Geppert R, Kaufmann O, Dietel M, Possinger K. Lack of HER-2/neu overexpression in non- Hodgkin's lymphoma. Anticancer Res 2004;24:3233-3237.
14. Muller M, Grunebach F, Kayser K, Vogel W, Nencioni A, Brugger W, et al. Expression of Her-2/neu on acute lymphoblastic leukemias: Implications for the development of immunotherapeutic approaches. Clin Cancer Res 2003; 9:3448-3453.
15. Bea S, Colomo L, Lopez-Guillermo A, Salaverria I, Puig X, Pinyol M, et al. Clinicopathologic significance and prognostic value of chromosomal imbalances in diffuse large B-cell lymphomas. J Clin Oncol 2004;22:3498-3506.
16. Harris L, Liotcheva V, Broadwater G, Ramirez M, Maimonis P, Anderson S. Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. J Clin Oncol 2001;19:1698-1706.
17. Gupta D, Middleton LP, Whitaker MJ, Abrams J. Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer. Am J Pathol 2003;119:381-387.
18. Kumamoto H, Sasano H, Taniguchi T, Suzki T, Moriya T, Ichinohasama R. Chromatic in situ hybridization analysis of Her-2/neu status in breast carcinoma: Application in screening of patients for trastuzumab (Herceptin®) therapy. Pathology Int 2001;51:579.
19. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller- Hermelink HK, Vardiman J, et al. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology 2000;36:69-86.
20. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230:1132-1139.
21. Carraway KL, Cantly LA. A neu acquaintance for erbB3 and erbB4: A role for receptor heterodimerization in growth signaling. Cell 1994;78:5-8.
22. Wen D, Peles E, Cupples R, Suggs SV, Bacus SS, Luo Y, et al. Neu differentiation factor: A transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. Cell 1992;69:559-572.
23. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target of therapy. Stem Cells 1998;16:413-428.
24. Zidan J, Dashkovsky I, Stayerman C, Basher W, Cozacov C, Hadary A. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 2005;93: 552-556.
25. Thomas DG, Giordano TJ, Sanders D, Biermann S, Sondak VK, Trent JC, et al. Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma. Cancer 2005;103:830-838.
26. Stein H. Diagnosis of Hodgkin's disease, Hodgkin's like anaplastic large cell lymphoma, and T cell/histiocyte-rich B cell lymphoma. In: Mason DY, Harris NL, editors. Human lymphoma: Clinical implications of the REAL classification, Vol. 52. London, England: Springer; 1999. pp 1-4.
27. Sgrignoli A, Abati A. Cytologic diagnosis of anaplastic large cell lymphoma. Acta Cytol 1997;41:1048-1052.
28. Gupta D, Middleton L, Whitaker M, Abrams J. Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer. Am J Clin Pathol 2003;119:381-387.